In most things in life, experts don't always agree on what's best.
Otherwise, they would not be expressing opinions, but merely facts. Even some facts are disputed among the boffins!
So when multiple investment gurus simultaneously rate the same large-cap S&P/ASX 200 Index (ASX: XJO) stock as a buy, your ears need to prick up.
Here's a recent case:
Short-term pain
'Frustrating' can't begin to describe the last few years for CSL Limited (ASX: CSL) investors.
Even now after the world has moved on from COVID-19, the ASX biotechnology stock has yet to reach its pre-pandemic prices.
To compound the troubles, during an economically turbulent 2023 when health shares have been lauded as a prudent play, CSL is well-and-truly down.
It's dived a whopping 14.9% since 13 June.
Ouch.
Seneca Financial investment advisor Arthur Garipoli admits the company's large US presence will do it no favours.
"Foreign currency movements will impact the company's fiscal year 2023 forecast profit," Garipoli told The Bull.
"CSL is expecting a foreign currency headwind of between US$230 million and US$250 million, up from US$175 million anticipated at its half year result."
…for long-term gain
However, the quality of the business and the continued post-pandemic recovery of its blood and plasma collection activities still makes it a buy for Garipoli and BW Equities equity salesperson Tom Bleakley.
"This blood products group has a solid track record of performance," said Garipoli.
"Despite weaker than expected near term earnings, we like the company's outlook."
Bleakley also acknowledged the foreign currency risk to CSL's short-term profits, but it's merely a buying window for him.
"The weaker share price provides an appealing opportunity to consider buying a quality company that we expect will recover over the medium to longer term."
Garipoli, too, agreed investors should take a long-term view in snapping up CSL shares.
"Recent share price weakness provides an attractive entry point for longer term investors."
The broader professional community concurs.
According to CMC Markets, 15 out of 18 analysts currently covering CSL reckon it's a buy.
Not one of them thinks it's a sell.
